888016-52-2Relevant academic research and scientific papers
2-Phenyl-4-piperazinylbenzimidazoles: Orally active inhibitors of the gonadotropin releasing hormone (GnRH) receptor
Pelletier, Jeffrey C.,Chengalvala, Murty,Cottom, Josh,Feingold, Irene,Garrick, Lloyd,Green, Daniel,Hauze, Diane,Huselton, Christine,Jetter, James,Kao, Wenling,Kopf, Gregory S.,Lundquist IV, Joseph T.,Mann, Charles,Mehlmann, John,Rogers, John,Shanno, Linda,Wrobel, Jay
, p. 6617 - 6640 (2008/12/22)
Antagonism of the gonadotropin releasing hormone (GnRH) receptor has shown positive clinical results in numerous reproductive tissue disorders such as endometriosis, prostate cancer and others. Traditional therapy has been limited to peptide agonists and
Gonadotropin releasing hormone receptor antagonists
-
Page/Page column 24, (2010/11/08)
The present invention relates to Gonadotropin Releasing Hormone (“GnRH”) (also known as Luteinizing Hormone Releasing Hormone) receptor antagonists.
